EA
PCRX icon

Endowment Advisers’s Pacira BioSciences PCRX Stock Holding History

Endowment Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-3,903
Closed -$113K – 2
2013
Q2 		$113K Buy
+3,903
New +$113K 100% 1

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Endowment Advisers's PCRX Position: Q3 2013 in Review

Endowment Advisers sold out of Pacira BioSciences (PCRX) in Q3 2013, closing a stake of 3,903 shares — an estimated $113K sold.

Endowment Advisers first reported a position in PCRX in Q2 2013 and held it in 1 quarter. The position peaked at $113K in Q2 2013. 130 funds tracked by Wall St. Rank hold PCRX as of Q3 2013.

  • Endowment Advisers reported no remaining Pacira BioSciences position as of Q3 2013 after selling out during the quarter.
  • Endowment Advisers sold 3,903 Pacira BioSciences shares in Q3 2013, an estimated $113K.
  • Endowment Advisers first reported a position in Pacira BioSciences in Q2 2013 and held it in 1 quarter.
  • Endowment Advisers's Pacira BioSciences position peaked at $113K in Q2 2013.
  • 130 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2013.

Based on Endowment Advisers's 13F filing for Q3 2013, filed 23 Oct 2013.